In re: Entresto (Sacubitril/Valsartan)
| NOVARTIS PHARMACEUTICALS CORPORATION |
| NANJING NORATECH PHARMACEUTICAL CO., LTD. |
| 23-2317 |
| August 23, 2023 |
| U.S. Court of Appeals, Federal Circuit |
| Patent - (ANDA) (Fed. Qst.) |
Docket Report
RSS Track this Docket
This docket was last retrieved on October 12, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 12
ORDER filed granting motion to consolidate appeals [ # 9 ]; Appeal Nos. 2023-2317 and 2023-2319 are consolidated, and thus one set of briefs should be filed for both appeals. The revised official caption is reflected in the order. The proceedings in the above-captioned appeals are stayed. Within 14 days of the issuance of the mandate in Appeal Nos. 2023-2218 et al., the parties are directed to inform the court as to how they believe these appeals should proceed. The Clerk of Court shall forward a copy of this order to the merits panel assigned to Appeal Nos. 2023-2218 et al. Service as of this date by the Clerk of Court. [955777] [23-2317, 23-2319] [LMS] [Entered: 10/12/2023 09:08 AM]
|
| Filing 11 Docketing Statement for the Appellee Nanjing Noratech Pharmaceutical Co., Ltd.. Service: 09/19/2023 by email. [951038] [23-2317] [Donald Mizerk] [Entered: 09/19/2023 02:32 PM] |
| Filing 10 Notice to Appellee Nanjing Noratech Pharmaceutical Co., Ltd. in 23-2317, 23-2319: The record of this case indicates that no Docketing Statement under FCR 47.6 has been filed. Failure to file required documents may result in dismissal or other action as deemed appropriate by the court. See FCR 25(h). Service as of this date by the Clerk of Court. [950941] [23-2317, 23-2319] [MMA] [Entered: 09/19/2023 11:51 AM] |
| Filing 9 MOTION of Appellant Novartis Pharmaceuticals Corporation and Appellee Nanjing Noratech Pharmaceutical Co., Ltd. to consolidate appeals (23-2317 with 23-2319), to stay appeal. Service: 09/06/2023 by email. [948147] [23-2317] [Deanne Maynard] [Entered: 09/06/2023 04:04 PM] |
| Filing 8 Notice of Related Case Information for Appellee Nanjing Noratech Pharmaceutical Co., Ltd.. Service: 09/05/2023 by email. [947803] [23-2317] [Donald Mizerk] [Entered: 09/05/2023 05:22 PM] |
| Filing 7 Certificate of Interest for Appellee Nanjing Noratech Pharmaceutical Co., Ltd.. Service: 09/05/2023 by email. [947801] [23-2317] [Donald Mizerk] [Entered: 09/05/2023 05:21 PM] |
| Filing 6 Entry of Appearance for Don J. Mizerk; Matthew M. Kamps as counsel for Appellee Nanjing Noratech Pharmaceutical Co., Ltd.. Service: 09/05/2023 by email. [947797] [23-2317] [Donald Mizerk] [Entered: 09/05/2023 05:17 PM] |
| Filing 5 Notice of Related Case Information for Appellant Novartis Pharmaceuticals Corporation. Service: 08/23/2023 by email. [945442] [23-2317] [Deanne Maynard] [Entered: 08/23/2023 05:54 PM] |
| Filing 4 Docketing Statement for the Appellant Novartis Pharmaceuticals Corporation. Service: 08/23/2023 by email. [945439] [23-2317] [Deanne Maynard] [Entered: 08/23/2023 05:52 PM] |
| Filing 3 Certificate of Interest for Appellant Novartis Pharmaceuticals Corporation. Service: 08/23/2023 by email. [945436] [23-2317] [Deanne Maynard] [Entered: 08/23/2023 05:48 PM] |
| Filing 2 Entry of Appearance for Deanne E. Maynard; Seth W. Lloyd; Nicholas N. Kallas; Christina Schwarz as counsel for Appellant Novartis Pharmaceuticals Corporation. Service: 08/23/2023 by email. [945434] [23-2317] [Deanne Maynard] [Entered: 08/23/2023 05:44 PM] |
| Filing 1 Appeal docketed. Received: 08/17/2023. [945341] Entry of Appearance due 09/06/2023. Certificate of Interest is due on 09/06/2023. Docketing Statement due 09/06/2023. Appellant's brief is due 10/23/2023. [MMA] [Entered: 08/23/2023 02:58 PM] |
Access additional case information on PACER
Access the Case Summary and Docket Report to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
